[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481440":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":50,"centralContacts":54,"locations":63,"responsibleParty":77,"collaborators":58,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":58,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":58,"enrollmentInfo":87,"targetDuration":58,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":58,"overallStatus":65,"whyStopped":58,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-RM26-RGD and 18F-FDG PET\u002F CT scan","EXPERIMENTAL","Within 2 week, each patient underwent PET\u002FCT scan after intravenous administration of 68Ga-RM26-RGD and 18F-FDG, respectively.",[13,14],"Drug: 68Ga-RM26-RGD","Drug: 18F-FDG",{"label":16,"type":10,"description":17,"interventionNames":18},"68Ga-RM26-RGD and 68Ga-RM26 PET\u002F CT scan","Within 2 week, each patient underwent PET\u002FCT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively.",[13,19],"Drug: 68Ga-RM26",{"label":21,"type":10,"description":22,"interventionNames":23},"68Ga-RM26-RGD and 68Ga-RGD PET\u002F CT scan","Within 2 week, each patient underwent PET\u002FCT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RGD, respectively.",[13,24],"Drug: 68Ga-RGD",[26,33,39,44],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","68Ga-RM26-RGD","Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)\u002F kg.",[9,21,16],[32],"68Ga-RM26-RGD injection",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"18F-FDG","18F-FDG injection",[9],[38],"Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)\u002Fkg.",{"type":27,"name":40,"description":29,"armGroupLabels":41,"otherNames":42},"68Ga-RM26",[16],[43],"68Ga-RM26 injection",{"type":27,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"68Ga-RGD","Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)\u002F kg.",[21],[49],"68Ga-RGD injection",[51],{"name":52,"affiliation":5,"role":53},"Zhaohui Zhu, MD,PHD","PRINCIPAL_INVESTIGATOR",[55,60],{"name":52,"role":56,"phone":57,"phoneExt":58,"email":59},"CONTACT","86+13611093752",null,"13611093752@163.com",{"name":52,"role":56,"phone":61,"phoneExt":58,"email":62},"86+19800370331","pumch_jacobwong@163.com",[64],{"facility":5,"status":65,"city":66,"state":58,"zip":58,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"RECRUITING","Beijing","China","CN",{"type":70,"coordinates":71},"Point",[72,73],116.39723,39.9075,{"lat":73,"lon":72},[76],{"name":52,"role":56,"phone":57,"phoneExt":58,"email":59},{"type":78,"investigatorFullName":58,"investigatorTitle":58,"investigatorAffiliation":58,"oldNameTitle":58,"oldOrganization":58},"SPONSOR","100481440","early-phase-1-68ga-rm26-rgd-petct-imaging-in-the-grpr-and-v3-positive-tumor-patients-100481440",false,"NCT05549024","68Ga-RM26-RGD PET\u002FCT Imaging in the GRPR and αvβ3 Positive Tumor Patients","Inclusion Criteria:\n\n* patients with confirmed or suspected breast\u002Fbrain\u002Fprostate cancer;\n* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET\u002FCT within 2 week;\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.","ALL","18 Years",{"count":88,"type":89},90,"ESTIMATED","INTERVENTIONAL",[92],"EARLY_PHASE1","Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET\u002FCT imaging to further verify its clinical application value.",[95,96,97,98],"Breast Cancer","Prostate Cancer","Brain Tumor","PET\u002FCT Imaging","2024-07-03",{"date":101,"type":102},"2024-07-05","ACTUAL",{"date":104,"type":102},"2022-08-16",{"date":106,"type":89},"2026-12-31",{"name":5,"class":6},1]